JP2019194190A5 - - Google Patents

Download PDF

Info

Publication number
JP2019194190A5
JP2019194190A5 JP2019102325A JP2019102325A JP2019194190A5 JP 2019194190 A5 JP2019194190 A5 JP 2019194190A5 JP 2019102325 A JP2019102325 A JP 2019102325A JP 2019102325 A JP2019102325 A JP 2019102325A JP 2019194190 A5 JP2019194190 A5 JP 2019194190A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
cancer
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019102325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019194190A (ja
JP6794496B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019194190A publication Critical patent/JP2019194190A/ja
Publication of JP2019194190A5 publication Critical patent/JP2019194190A5/ja
Priority to JP2020187991A priority Critical patent/JP6985486B2/ja
Application granted granted Critical
Publication of JP6794496B2 publication Critical patent/JP6794496B2/ja
Priority to JP2021191088A priority patent/JP7335310B2/ja
Priority to JP2023133133A priority patent/JP7650923B2/ja
Priority to JP2025038864A priority patent/JP2025102800A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019102325A 2011-10-28 2019-05-31 癌幹細胞特異的分子 Active JP6794496B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2020187991A JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子
JP2021191088A JP7335310B2 (ja) 2011-10-28 2021-11-25 癌幹細胞特異的分子
JP2023133133A JP7650923B2 (ja) 2011-10-28 2023-08-17 癌幹細胞特異的分子
JP2025038864A JP2025102800A (ja) 2011-10-28 2025-03-12 癌幹細胞特異的分子

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011237438 2011-10-28
JP2011237438 2011-10-28
JP2012091142 2012-04-12
JP2012091142 2012-04-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017228927A Division JP6580112B2 (ja) 2011-10-28 2017-11-29 癌幹細胞特異的分子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020187991A Division JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子

Publications (3)

Publication Number Publication Date
JP2019194190A JP2019194190A (ja) 2019-11-07
JP2019194190A5 true JP2019194190A5 (enExample) 2020-03-12
JP6794496B2 JP6794496B2 (ja) 2020-12-02

Family

ID=48167907

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2013540843A Active JP6291254B2 (ja) 2011-10-28 2012-10-26 癌幹細胞特異的分子
JP2017228927A Active JP6580112B2 (ja) 2011-10-28 2017-11-29 癌幹細胞特異的分子
JP2019102325A Active JP6794496B2 (ja) 2011-10-28 2019-05-31 癌幹細胞特異的分子
JP2020187991A Active JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子
JP2021191088A Active JP7335310B2 (ja) 2011-10-28 2021-11-25 癌幹細胞特異的分子
JP2023133133A Active JP7650923B2 (ja) 2011-10-28 2023-08-17 癌幹細胞特異的分子
JP2025038864A Pending JP2025102800A (ja) 2011-10-28 2025-03-12 癌幹細胞特異的分子

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013540843A Active JP6291254B2 (ja) 2011-10-28 2012-10-26 癌幹細胞特異的分子
JP2017228927A Active JP6580112B2 (ja) 2011-10-28 2017-11-29 癌幹細胞特異的分子

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020187991A Active JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子
JP2021191088A Active JP7335310B2 (ja) 2011-10-28 2021-11-25 癌幹細胞特異的分子
JP2023133133A Active JP7650923B2 (ja) 2011-10-28 2023-08-17 癌幹細胞特異的分子
JP2025038864A Pending JP2025102800A (ja) 2011-10-28 2025-03-12 癌幹細胞特異的分子

Country Status (4)

Country Link
US (3) US20140302511A1 (enExample)
EP (2) EP3603671A3 (enExample)
JP (7) JP6291254B2 (enExample)
WO (1) WO2013062083A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
JP5808054B2 (ja) 2009-12-25 2015-11-10 中外製薬株式会社 Nog樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法
CN103328626B (zh) 2010-10-06 2017-02-08 中外制药株式会社 癌干细胞群及其制备方法
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
EP3603671A3 (en) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
EP2817620B1 (en) * 2012-02-22 2016-06-01 Verik Bio, Inc. A system for immunotherapy targeting tumor propagation and progression
WO2014104165A1 (ja) 2012-12-27 2014-07-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
WO2014208482A1 (ja) * 2013-06-24 2014-12-31 中外製薬株式会社 ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
CA2953663A1 (en) * 2014-06-25 2015-12-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Identification of cancer stem cells and use of same for diagnosis and treatment
KR101779147B1 (ko) * 2014-07-04 2017-09-20 연세대학교 산학협력단 Kiaa1199를 이용한 췌장암의 진단 또는 치료용 조성물
JP2016028569A (ja) * 2014-07-16 2016-03-03 学校法人慶應義塾 がん幹細胞集団の調製方法、異種移植片の調製方法、スクリーニング方法、miR−34aの発現量を低下させる方法及びがん幹細胞増殖抑制剤
EP3394107A1 (en) * 2015-12-22 2018-10-31 AbbVie Stemcentrx LLC Novel anti-tnfsf9 antibodies and methods of use
WO2018181276A1 (ja) 2017-03-28 2018-10-04 学校法人慶應義塾 ヒト組織幹細胞及びその使用
JP7446224B2 (ja) * 2018-08-08 2024-03-08 中外製薬株式会社 がん組織またはがん組織に類似した組織の培養方法
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5573924A (en) * 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
BR9713294A (pt) 1996-09-26 2000-10-17 Chugai Pharmaceutical Co Ltd "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano"
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424602C (en) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-producing cell
CA2427858A1 (en) 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CA2402459A1 (en) 2000-12-01 2002-06-06 Central Institute For Experimental Animals Method of producing a mouse suitable for engraftment, differentiation and proliferation of heterologous cells, mouse produced by this method and use of the mouse
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
AU2003238897A1 (en) * 2002-06-05 2003-12-22 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2006113909A2 (en) * 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
CA2525909A1 (en) 2003-05-16 2004-11-25 Kyowa Hakko Kogyo Co., Ltd. Novel stem cell derived from adult tissue and use thereof
JP2005035943A (ja) 2003-07-16 2005-02-10 Chemo Sero Therapeut Res Inst 悪性腫瘍細胞増殖抑制剤
CA2447400A1 (en) 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
WO2005035740A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 無血清馴化したゲノム改変細胞
JP2005206508A (ja) * 2004-01-22 2005-08-04 Chemo Sero Therapeut Res Inst 悪性腫瘍細胞増殖抑制抗体
CA2560742A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2005111076A1 (en) * 2004-05-12 2005-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (n4) as a marker for cancer prognosis
US20080152700A1 (en) 2004-06-01 2008-06-26 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
WO2006014999A2 (en) * 2004-07-27 2006-02-09 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
WO2006039671A2 (en) 2004-09-29 2006-04-13 Central Institute For Experimental Animals Gene markers of tumor metastasis
WO2006051405A2 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
US20090081221A1 (en) 2004-11-15 2009-03-26 Kirin Beer Kabushiki Kaisha Method for suppressing cancer cell metastasis and pharmaceutical composition for use in the method
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1907572A2 (en) 2005-07-26 2008-04-09 Procure Therapeutics Limited Prostate stem cell markers
EA016186B1 (ru) * 2005-09-26 2012-03-30 Медарекс, Инк. Человеческие моноклональные антитела к cd70 и их применение
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
EP1792979A1 (en) 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells
WO2007124125A2 (en) * 2006-04-21 2007-11-01 Stowers Institute For Medical Research Methods of identifying stem cells in normal and cancerous tissues and related progeny cells
WO2007132883A1 (ja) 2006-05-17 2007-11-22 Yokohama City University 肝臓癌の鑑別、疾患ステージの判定又は予後の予測方法及びキット
WO2007145901A1 (en) 2006-06-06 2007-12-21 University Of Tennessee Research Foundation Compositions enriched in neoplastic stem cells and methods comprising same
WO2009045201A1 (en) * 2006-08-02 2009-04-09 Biogen Idec Ma Inc. Cancer stem cells
WO2008017171A1 (en) 2006-08-11 2008-02-14 Ao-Forschungsinstitut Davos Identification and selection of stem cells being committed to differentiate to a specific type for obtaining a homogeneous population of stem cells
JP2010502220A (ja) * 2006-09-05 2010-01-28 メダレックス インコーポレーティッド 骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
WO2008033393A2 (en) 2006-09-11 2008-03-20 University Of Florida Isolation, expansion and uses of tumor stem cells
GB2442059A (en) 2006-09-19 2008-03-26 Ist Superiore Sanita Test for cancer of the gastrointestinal tract
AU2007312367B2 (en) * 2006-10-12 2012-09-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
JP2008102012A (ja) 2006-10-19 2008-05-01 Kanazawa Univ 癌幹細胞の同定および単離方法
EP2109668A4 (en) 2007-01-22 2011-10-05 Macrogenics West Inc HUMAN CANCER STEM CELLS
JP2008182912A (ja) 2007-01-29 2008-08-14 Nippon Kayaku Co Ltd 癌幹細胞の培養方法、および癌幹細胞
NZ581395A (en) * 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2008149803A1 (ja) 2007-06-06 2008-12-11 The University Of Tokyo 表面抗原マーカーを用いた急性リンパ性白血病における癌幹細胞の分離同定方法
JP5931336B2 (ja) 2007-07-02 2016-06-08 オンコメッド ファーマシューティカルズ インコーポレイテッド がんを処置および診断するための組成物および方法
US20110244502A1 (en) 2007-08-10 2011-10-06 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
GB2465940A (en) 2007-10-01 2010-06-09 Hospital For Sick Children Neural tumor stem cells and methods of use thereof
WO2009064301A1 (en) * 2007-11-15 2009-05-22 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
US20100267571A1 (en) 2007-12-14 2010-10-21 Chugai Seiyaku Kabushiki Kaisha Novel method for specimen preparation, which ensures preservation of tissue morphology and nucleic acid quality
WO2009111067A2 (en) 2008-03-07 2009-09-11 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation
WO2009135181A2 (en) * 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2010009121A2 (en) 2008-07-15 2010-01-21 University Of Florida Research Foundation, Inc. Colon stem cells associated with colitis and colorectal cancer and methods of use
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
WO2010067487A1 (en) * 2008-12-12 2010-06-17 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
CN102405237A (zh) * 2009-03-06 2012-04-04 卡罗拜奥斯制药公司 利用EphA3抗体治疗白血病和慢性骨髓增生性疾病
EP2414396B1 (en) * 2009-03-30 2015-02-25 Edimer Biotech S.a. Preparation of isolated agonist anti-edar monoclonal antibodies
JP2012524083A (ja) * 2009-04-20 2012-10-11 ジェネンテック, インコーポレイテッド アジュバント癌治療
TW201105347A (en) * 2009-04-28 2011-02-16 Chugai Pharmaceutical Co Ltd Pharmaceutical compositions for maintenance therapy containing HLA class I-recognizing antibody as the active ingredient
US20120141501A1 (en) * 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
JP5808054B2 (ja) 2009-12-25 2015-11-10 中外製薬株式会社 Nog樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
CN103328626B (zh) 2010-10-06 2017-02-08 中外制药株式会社 癌干细胞群及其制备方法
KR101463182B1 (ko) * 2011-01-13 2014-11-21 연세대학교 산학협력단 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
EP3603671A3 (en) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
WO2014104165A1 (ja) 2012-12-27 2014-07-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
US10504315B2 (en) 2013-08-05 2019-12-10 Ncr Corporation Clamping of media items

Similar Documents

Publication Publication Date Title
JP2019194190A5 (enExample)
JP6603685B2 (ja) クロストリジウム・ディフィシレの主要な外毒素TcdA及びTcdBに対する中和抗体
ES2918375T3 (es) Tratamientos contra el cáncer usando combinaciones de inhibidores de la ruta de PI3K/Akt y ERK
TW202034959A (zh) 抗體-藥物結合物與parp抑制劑之組合
JP2019527706A5 (enExample)
JP2009539380A5 (enExample)
TW201427664A (zh) Tec家族激酶抑制劑佐劑療法
ES2839456T3 (es) Proteína 2 que contiene el dominio del esperma móvil y del cáncer
JP2014524746A5 (enExample)
HRP20151261T1 (hr) Sastavi i postupci za lijeäśenje i dijagnosticiranje raka
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2021502980A (ja) Atp放出の効果の強力化
JP2018523686A5 (enExample)
BR112014002613A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
EA201892541A1 (ru) Гуманизированные анти-il-1r3 антитела
JP2017113019A5 (enExample)
Rivera-Valentin et al. Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy
CN110698559B (zh) 一种tpbg抗体及其制备方法、其偶联物和应用
WO2014151606A4 (en) Methods of treating pancreatic cancer
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
JP2014223083A5 (enExample)
CN110114087A (zh) β-连环蛋白作为生物标记物用于使用抗DKK-1抗体治疗癌症的用途
CN111278992A (zh) 用抗egfr抗体治疗癌症的组合物和方法
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b